For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Resmed Inc’s stock clocked out at $248.38, down -2.91% from its previous closing price of $255.83. In other words, the price has decreased by -$2.91 from its previous closing price. On the day, 1.26 million shares were traded. RMD stock price reached its highest trading level at $253.885 during the session, while it also had its lowest trading level at $237.625.
Ratios:
To gain a deeper understanding of RMD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 26.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.50. For the most recent quarter (mrq), Quick Ratio is recorded 2.13 and its Current Ratio is at 2.89. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on September 18, 2025, initiated with a Buy rating and assigned the stock a target price of $330. RBC Capital Mkts Upgraded its Sector Perform to Outperform on July 15, 2025, while the target price for the stock was maintained at $294.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Sandercock Brett bought 1,000 shares for $244.16 per share.
Rider Michael J bought 50 shares of RMD for $12,208 on Dec 01 ’25. On Nov 25 ’25, another insider, De Witte Jan, who serves as the Director of the company, sold 2,055 shares for $255.00 each. As a result, the insider received 524,025 and left with 4,261 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RMD now has a Market Capitalization of 36255109120 and an Enterprise Value of 35717611520. As of this moment, Resmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.42, and their Forward P/E ratio for the next fiscal year is 20.54. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.90 while its Price-to-Book (P/B) ratio in mrq is 5.92. Its current Enterprise Value per Revenue stands at 6.794 whereas that against EBITDA is 18.426.
Stock Price History:
The Beta on a monthly basis for RMD is 0.87, which has changed by 0.0059535503 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, RMD has reached a high of $293.81, while it has fallen to a 52-week low of $199.92. The 50-Day Moving Average of the stock is -4.98%, while the 200-Day Moving Average is calculated to be -1.58%.
Shares Statistics:
It appears that RMD traded 1.06M shares on average per day over the past three months and 973120 shares per day over the past ten days. A total of 145.94M shares are outstanding, with a floating share count of 145.04M. Insiders hold about 0.63% of the company’s shares, while institutions hold 65.86% stake in the company. Shares short for RMD as of 1763078400 were 10647780 with a Short Ratio of 10.01, compared to 1760486400 on 8964374. Therefore, it implies a Short% of Shares Outstanding of 10647780 and a Short% of Float of 8.4.
Dividends & Splits
With its trailing 12-month dividend rate of 2.19, RMD has a forward annual dividend rate of 2.26. Against a Trailing Annual Dividend Yield of 0.0085603725. The stock’s 5-year Average Dividend Yield is 0.83. The current Payout Ratio is 22.30% for RMD, which recently paid a dividend on 2025-11-13 with an ex-dividend date of 2025-11-13. Stock splits for the company last occurred on 2010-08-31 when the company split stock in a 2:1 ratio.
Earnings Estimates
Resmed Inc (RMD) is currently under the scrutiny of 13.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $2.77, with high estimates of $2.86 and low estimates of $2.69.
Analysts are recommending an EPS of between $11.24 and $10.35 for the fiscal current year, implying an average EPS of $10.9. EPS for the following year is $12.02, with 19.0 analysts recommending between $12.63 and $11.63.
Revenue Estimates
In. The current quarter, 16 analysts expect revenue to total $1.4B. It ranges from a high estimate of $1.43B to a low estimate of $1.36B. As of. The current estimate, Resmed Inc’s year-ago sales were $1.28BFor the next quarter, 16 analysts are estimating revenue of $1.41B. There is a high estimate of $1.44B for the next quarter, whereas the lowest estimate is $1.39B.
A total of 26 analysts have provided revenue estimates for RMD’s current fiscal year. The highest revenue estimate was $5.67B, while the lowest revenue estimate was $5.54B, resulting in an average revenue estimate of $5.6B. In the same quarter a year ago, actual revenue was $5.15BBased on 26 analysts’ estimates, the company’s revenue will be $6.02B in the next fiscal year. The high estimate is $6.17B and the low estimate is $5.91B.
